Noble Introduces New Preclinical Research Models

Request Quote
Noble Life Sciences

Advance Your Oncology Research with

Clinically Relevant PDX Models

Enhancing Preclinical Cancer Research with Patient-Derived Xenografts (PDX)

Traditional preclinical models often fail to predict clinical efficacy and drug resistance. Patient-Derived Xenograft (PDX) models, however, provide a revolutionary approach to preclinical oncology research, enabling clinically relevant drug testing, biomarker discovery, and personalized medicine development.

Speak to PDX Expert
Request a Quote

We offer a diverse portfolio of PDX models, cutting-edge translational research tools, and customized study designs to accelerate your oncology pipeline and improve preclinical-to-clinical translation.

Preclinical CRO research studies Noble Life Sciences

What is a Patient-Derived Xenograft (PDX) Model?

Definition & Significance

PDX models are developed by implanting tumor tissues directly from patients into immunodeficient mice, allowing the tumors to maintain their genetic, histological, and microenvironmental integrity.

  • Preserve tumor heterogeneity –
    More representative of actual patient tumors
  • Maintain genetic stability –
    Minimizing clonal selection seen in cell lines
  • Improve clinical predictability –
    More accurate drug response and resistance studies

PDX models serve as a powerful platform for evaluating novel cancer therapies, from targeted agents to immunotherapies.

How Do PDX Models Compare to Other Preclinical Models?

Comparison: PDX vs. Other Preclinical Cancer Models

Model Type Key Advantages Ideal Applications
PDX Models High clinical relevance, retains tumor heterogeneity Biomarker-driven drug development, resistance studies, personalized medicine
CDX Models Rapid, reproducible tumor growth but lacks heterogeneity Early-stage screening, efficacy testing
Syngeneic Models Fully immunocompetent mice, ideal for immuno-oncology Checkpoint inhibitors, CAR-T, NK cell therapies

PDX models bridge the gap between preclinical research and clinical outcomes, making them the gold standard for oncology drug development.

Noble Life Sciences PDX Model Capabilities

Comprehensive PDX Model Portfolio

  • Fresh & Cryopreserved PDX Tumor Models
  • Orthotopic & Subcutaneous PDX Models
  • Humanized PDX Mouse Models for Immuno-Oncology
  • PDX Tumor Organoids for High-Throughput Drug Screening

Cancer Types Supported

Breast Cancer

TNBC, HER2+, ER/PR+

Lung Cancer

NSCLC, SCLC, KRAS-mutated

Colorectal Cancer

MSI-H, MSS, KRAS-mutated

Pancreatic Cancer

PDAC, Metastatic Models

Ovarian Cancer

HGSOC, Low-Grade Serous, Platinum-Resistant

Prostate Cancer

Castration-Resistant, AR+ Tumors

Glioblastoma & Brain Tumors

Leukemia & Lymphomas

Rare & Pediatric Tumor Models

Our extensive PDX library ensures a relevant model for your specific oncology research needs.

<br /> Cutting-Edge Technologies Supporting PDX Research<br />

Cutting-Edge Technologies Supporting PDX Research

5

2D & 3D In Vitro Assays

Accelerating PDX model screening

5

Single-Mouse Trials (SMT)

Precision oncology with patient-matched therapies

5

PDX Tumor Organoids & 3D Culture Systems

High-throughput screening

5

Multiplexed Biomarker Analysis & Immune Profiling

Deep tumor characterization

5

Whole-Exome & RNA Sequencing

Comprehensive genomic profiling

5

In Vivo Imaging

Real-time tumor growth and metastasis tracking

We integrate AI, imaging, and genomic tools to refine PDX model selection and enhance translational oncology research.

Why Choose Noble for PDX Model Studies?

5

Diverse, Well-Characterized PDX Library

Covering solid tumors, hematologic malignancies, and rare cancers

5

GLP-Compliant Preclinical Oncology Services

Ensuring regulatory compliance for IND-enabling studies

5

Seamless Integration from Early Discovery to IND-Enabling Studies

Bridging the gap between preclinical and clinical phases

5

Customized Study Design & Expert Scientific Consultation

Tailored solutions for specific research objectives

5

Fast Turnaround Times with Cost-Effective Solutions

Maximizing efficiency without compromising quality

Partnering with Noble ensures high-quality, actionable data to support oncology drug development.
Noble Life Sciences Oncology Research Cancer Research

PDX Models Transforming Oncology Drug Development

PDX models have become the gold standard in preclinical oncology research, offering unparalleled insights into drug efficacy, tumor resistance, and patient-specific therapies. With an extensive PDX model portfolio, advanced translational research tools, and regulatory expertise, Noble Life Sciences is your ideal CRO partner.
Speak to a PDX Expert

Explore additional preclinical tumor models to support your oncology research.

Syngeneic Mouse Models
Xenograft Model
Orthotopic Tumor Models
Cancer Models
PDX Research Preclinical CRO

Get Started with Noble PDX Research Services

Request a Quote